Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 4, 2026

Iconic national office retailer closing stores, no bankruptcy

View original at finance.yahoo.com
Iconic national office retailer closing stores, no bankruptcy Amazon’s skyrocketing success had a disruptive effect on traditional sales in the global retail industry…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Customers were using fewer office supplies and migrating to online shopping, reducing the ability to sell add-on items and making them more value-conscious. Staples will close about 225 stores by 2015, with expectations to cut costs by $500 million as a result.

    80% confidence
  • This transaction provides a substantial premium for shareholders and will improve the company's position for the next phase of growth. Atlas brings operational expertise and resources that will fast forward B2B growth initiatives.

    80% confidence
  • In the first six months of 2025, the Business Solutions unit generated 52% of total sales. That's up from 51.3% a year earlier, driven by slower declines in B2B compared with retail

    80% confidence
  • Amazon Basics captures 12% of online office supply sales

    80% confidence
  • In 2024, ODP reported revenue of $7 billion, a far cry south of its post-merger total and revenue of $11.7 billion 10 years ago in 2015

    80% confidence
  • U.S. office supplies sales revenue across physical and digital retail channels totaled $11.5 billion in 2024, suggesting a 5% year-over-year decline, as total unit demand dropped 2%

    80% confidence
  • 40% of office workers still prefer handwritten notes, despite using digital tablets

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Iconic national office retailer closing stores, no bankruptcy — Source | Via News | Via News